Varlitinib is under clinical development by Aslan Pharmaceuticals and currently in Phase III for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase III drugs for Gastroesophageal (GE) Junction Carcinomas have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Varlitinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Varlitinib overview
ASLAN-001 (varlitinib) is under development for the treatment of solid tumors such as breast cancer (Her2-positive), ovarian cancer, gastro-oesophageal junction, colorectal cancer, cholangiocarcinoma, gastric cancer (second-line therapy), gallbladder cancer, metastatic hepatocellular carcinoma and carcinoma of ampulla of vater. The drug candidate is administered through the oral route. It targets HER1, HER2, HER3 and HER4 receptors.
It was also under development for pancreatic cancer and metastatic gastric cancer, gastro-oesophageal junction cancer (second-line therapy) and metastatic biliary tract cancer (first line therapy).
Aslan Pharmaceuticals overview
Aslan Pharmaceuticals is a clinical-stage biotechnology company that develops novel therapeutics for various oncology diseases. The company’s pipeline products include Varlitinib, ASLAN003, ASLAN004 and ASLAN002. Its Varlitinib is a pan-HER inhibitor used for the treatment of biliary tract cancer, gastric cancer, breast cancer and colorectal cancer. Aslan Pharmaceuticals’ ASLAN003 is a DHODH inhibitor used for the treatment of acute myeloid leukemia; ASLAN004 is an IL-4/IL-13 receptor inhibitor used for the treatment of asthma and atopic dermatitis; and ASLAN002 is a RON/MET inhibitor used for the treatment of solid tumors. The company conducts regional clinical development programs across Asia. It operates its offices in Singapore, Taiwan and China. Aslan Pharmaceuticals is headquartered in Singapore.
For a complete picture of Varlitinib’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
